News|Articles|September 29, 2026

Heart Failure Society of America 2026 Preview: 6 Trials to Watch

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

The Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 is scheduled to begin on October 9, 2026, and is expected to present the clearest view of how heart failure (HF) care has evolved in the past year. Readouts from major trials of both investigational drugs and operations to improve major biomarkers and reduce side effects have been announced, with many more likely to be revealed once the conference begins.

Related to this article

October 2nd, 2026

9 Cardiology Headlines You Missed in Q3 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

October 1st, 2026

7 Cardiology Headlines You Missed in September 2026

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

October 5th, 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.